Results 211 to 220 of about 75,315 (267)
The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma. [PDF]
Sci RepWang R +5 more
europepmc +1 more source
Is Salvage Autologous Stem Cell Transplantation Still a Viable Treatment Option in Relapsed Myeloma Patients? [PDF]
Medicina (Kaunas)Čemažar L, Škerget M, Skopec B.
europepmc +1 more source
"B" symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation. [PDF]
Ann HematolChromik K +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Autologous stem cell transplantation in scleroderma
La Presse Médicale, 2021Patients with severe rapidly progressive systemic sclerosis (SSc) have a poor prognosis. Standard immunosuppressive therapies may have modest effects on stabilizing disease, but they fail to improve overall survival. Hematopoietic stem cell transplant (HSCT) is the first treatment to induce disease-modifying therapeutic benefits in rapidly progressive ...
Dominique Farge +3 more
openaire +2 more sources
Advances in Autologous Stem Cell Transplantation
Cancer Investigation, 1997INTRODUCTION In the past 10 years, autologous stem cell transplantation (ASCT) has emerged as a major new form of treatment for a variety of malignant diseases. Indeed, the overall number of autologous transplants registered with the Autologous Blood and Marrow Transplant Registry (ABMTR) in a 5-year period ending in 1994 was 16,561 (1).
J R, Mason, A D, Ho
openaire +2 more sources
Overview of autologous stem cell transplantation
Critical Reviews in Oncology/Hematology, 2000There has been a dramatic increase in the number of autologous peripheral blood stem cell transplants over the last decade. Faster recovery of cell counts, lesser transplant morbidity, shorter hospital stay and reduced cost compared with marrow autografts have been the main advantages of autologous peripheral blood cell over marrow transplants. In this
N, Saba, R, Abraham, A, Keating
openaire +2 more sources
Autologous Stem Cell Transplantation: Introduction
Seminars in Hematology, 2007Item does not contain ...
de Witte, T.J.M., de Witte, T.J.M.
openaire +2 more sources
Autologous stem cell transplantation in multiple myeloma
Panminerva Medica, 2021The treatment of patients with multiple myeloma has changed in the last decades, with an improved median survival of 8-10 years. The current treatment for newly diagnosed multiple myeloma patients eligible for autologous transplantation consists of 4 phases: pretransplant, induction, transplant, post-transplant consolidation and maintenance. Even today,
Giuseppina, Ricciuti +4 more
openaire +2 more sources
Autologous Stem Cell Transplantation in Lymphoma
Seminars in Hematology, 2007High-dose therapy (HDT) followed by autologous transplantation of hematopoietic stem cells (ASCT) is frequently performed in patients with lymphoma. For many subentities, reliable results from prospective randomized studies are missing. In Hodgkin's disease (HD), HDT/ASCT is a standard indication for patients with chemosensitive first relapse. Patients
Norbert, Schmitz +2 more
openaire +2 more sources
Autologous Stem Cell Transplantation for T-Cell Lymphomas
Seminars in Hematology, 2014Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of T-cell malignancies characterized by a very poor outcome. The optimal treatment for PTCLs remains controversial. The role of stem cell transplantation in PTCLs has been investigated; however, no randomized control studies specifically dedicated to PTCLs are currently available ...
Giulia, Perrone +2 more
openaire +2 more sources